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  1Abstract:   
In this paper I discuss the fact that economists define optimal IP rights as a continuum of options in 
three dimensions: height, breadth and length. At the operational level we see the impossibility of 
multiplying rights indefinitely (due to prohibitive transaction costs), as well as the use of a limited 
number of IP tools which have led to the implementation of flexibilities. These flexibilities are 
designed to limit certain perverse effects of rights ill-adjusted to the characteristics of some economic 
sectors (agricultural biotechnologies, pharmacy, etc.). In this context, I analyse how these flexibilities 









  2The application of intellectual property rights and their impact on innovation are essential issues in 
every country's development and growth. At the WTO (World Trade Organisation), in parallel with 
negotiations on rules of access to goods and service markets – commonly referred to as "trade 
liberalization" – negotiations concern the TRIPS agreements (trade-related aspects of intellectual 
property). The official aim of these negotiations, especially Article 27 on patents, is to establish a 
minimum level of intellectual property rights at international level, in order to ensure the 
protection of innovations and their diffusion towards those countries that have adequate intellectual 
property rights. These agreements are supposed to favour the development of innovations and their 
commercialization world wide, to promote growth, and to reduce poverty (Article 7)
2. Are things all 
that simple? This is what I set out to examine in this article. 
In the first section, in order to understand the implications of the TRIPS agreements, I consider from a 
theoretical perspective the implications of intellectual property regarding the production of 
innovations. In the second section I then analyse the conditions required for the implementation of 
intellectual property rights. Finally, in the last section I present the TRIPS agreement and TRIPS+ 
(bilateral free trade agreements between developing countries and the USA or EU) and their positive 
and negative impacts on developing countries and international trade. 
 
1. General review of incentives to innovate and to diffuse innovations  
In economics, promoting innovation and its diffusion corresponds to the objective of "seeking an inter-
temporal social optimum". As Henry, Trommetter and Tubiana noted in 2003: "In situations of 
endogenous growth – the most suitable framework for studying the motivations and effects of 
inventive (or innovative) activity and technological progress –, two forms of competition are at play. 
First, competition for triggering innovation and taking advantage of it
3; second, competition in the 
                                                 
2 "The protection and enforcement of intellectual property rights should contribute to the promotion of 
technological innovation and to the transfer and dissemination of technology, to the mutual advantage of 
producers and users of technological knowledge and in a manner conducive to social and economic welfare, 
and to a balance of rights and obligations", Trips Agreement, Article 7. 
3 Or deriving the benefit of reputation, in the case of R&D institutions where profit is not the main motivation 
("open science"). 
  3market for products, that is, the goods or services that innovation helps to create or improve, or whose 
production costs it reduces". 
 
1.1. Incentives for firms to innovate and to diffuse their innovations 
Which characteristics are mobilized to encourage firms to innovate and to diffuse their innovations?  
 
1.1.1.   Incentives for firms to innovate 
If firms are to be encouraged to innovate, they have to be given incentives to invest in research and 
development (R&D). In neoclassical theory, if innovation can easily be imitated
4 – therefore at a low 
cost –, and in the absence of any other hypothesis, competition in the innovative product market is 
perfect; thus, at the market equilibrium, the price corresponds to the marginal cost of production. This 
situation does not encourage firms to innovate since they are unable to derive a return on their R&D 
investments. Irrespective of how easily innovation can be imitated, innovators have to be ensured of a 
return on their R&D investments. There are several options in this respect: 
* There is external funding for R&D from government or foundations, and the firm's 
investments in R&D are nil. This provides the right conditions for combining incentives to 
innovate, with an innovation market, characterized by pure and perfect competition. 
* Since investment in R&D is positive, a rent needs to be created for the innovative firm. This 
rent is guaranteed by the recognition of an intellectual property right which, for the innovator, 
creates a temporary monopoly
5 on the commercialization
6 and diffusion of the innovation. 
                                                 
4 We need to bear in mind that in most industries, secrecy is preferred over protection via intellectual property 
rights, in the vast majority of cases. 
5 The monopoly has to be temporary to encourage firms to adopt strategies of sequential innovations: ex ante 
competition, innovative monopoly, ex post competition when innovation falls into the public domain, etc. 
6 Any intellectual property allows the right to exclude rivals from the use of an innovation, but does not 
necessarily grant a use right to that innovation (e.g. development phase during authorization to 
commercialize drugs). 
  4The first option is certainly the most favourable from the social welfare point of view, but since 
external funds are not unlimited, today they are used primarily to finance research in "orphan" sectors
7 
and in the case of innovations in fundamental research. For instance, in 2005 the Bill and Melinda 
Gates Foundation invested US$300m in research to develop a malaria vaccine
8. In these external 
mechanisms of R&D financing, the innovator can be compensated (remunerated) in the form of a call 
for tenders, a prize (Master (2004)), and so on.  
To implement the second option, economists (e.g. Gilbert and Shapiro (1990)) propose that optimal 
property rights be found and implemented; that is, property rights whose characteristics allow for a 
social optimum to be achieved
9. This means defining what can be protected – height of intellectual 
property –, for how long – length
10 –, and with what scope – breadth
11 –, and thus facilitating the 
creation and diffusion of innovations and of related information. 
In this context the monopoly situation stemming from the intellectual property system is socially 
acceptable because it ensures the social optimum. To see this we need to reason in relative terms: what 
is the alternative to a monopoly on an innovation? – a market "without innovation". This means that 
with a monopoly price, fewer consumers will have access to the innovative good, compared to a 
competitive market (unfavourable situation for consumers). On the other hand, at the competitive 
market price there would be no supply function for this innovative good, due to the disincentives for 
the innovator to invest in R&D (situation even more unfavourable for consumers). The monopoly is 
then a “necessary ill”, to achieve a second-best social optimum when it is associated with the absence 
of unlimited external funding of research and with optimal intellectual property rights. Theoretically, a 
                                                 
7 An orphan sector is a sector in which the demand function never intersects with the supply function, and where 
the societal stakes are high in terms of global public goods, whether these pertain to the right to health, food 
or a good environment. 
8 Source: http://www.gatesfoundation.org 
9 For a survey of the stakes of intellectual property, see Langinier and Moschini (2002). 
10 The duration of intellectual property rights must be long enough to cover the irrecoverable costs of R&D, and 
short enough to ensure competition in the product market conducive to new R&D expenditures, so that future 
innovations can be developed. 
11 The scope of the patent must be sufficiently broad to limit risks of imitation, and sufficiently narrow to ensure 
competition in the search for future innovations. 
  5continuum of intellectual property rights exists in all three dimensions (height, length and breadth), 
including the absence of intellectual property rights if the height is nil. 
 
1.1.2. Incentives for firms to diffuse their innovations and information on those 
innovations 
The stakes involved in diffusing innovations and related information are threefold: 
•  it allows a maximum number of consumers to be able to benefit from the innovation; the 
innovation is diffused in countries in which there is a market and therefore also a demand 
function compatible with the innovator's supply function, as well as adequate intellectual 
property rights; 
•  it increases incentives to innovate. Favouring the diffusion of innovation towards other 
countries increases the size of the potential market. And the bigger the potential market, the 
stronger incentives to invest in R&D will be. Incentives to innovate by proposing a monopoly 
situation to the innovator are effective if sufficiently large local, national, regional and 
international markets exist;  
•  it increases the incentives for rival firms to innovate (in the country or in other countries) 
partly by informing them on protected innovations (thus limiting duplication in research) and 
partly by favouring spillovers and cumulative innovations. This third point is the most 
controversial since it depends on the scope granted to an intellectual property right
12. In this 
respect, Henry, Trommetter and Tubiana (2003) point out that "knowledge accumulated from 
past innovations is a public good
13 on which subsequent innovations will be based". 
The decision to diffuse an innovation and/or information on an innovation in a third country will 
depend on various factors: 
                                                 
12 The risk relative to spillovers that would be too great for an innovator, would be that the area of the market 
after diffusion of the innovation were more limited than before its diffusion. 
13 In the economic sense of a public good (whose use by one does not reduce its potential use by others) but not 
necessarily in the legal sense. 
  6•  Consumers' capacity for adopting the innovation (as an intermediate or final good). Does a 
demand function for innovation exist? Is this demand function compatible with the 
innovator's supply function? The utility stemming from the consumption of the innovation 
as a final good is determined by the price that the consumer is willing to pay for access to 
the innovation (consumer's marginal utility). The utility related to use of the innovation as 
an intermediate consumption in a production process is more complex to measure. For 
instance, if use of the innovation allows the production of another good to be doubled, 
what are the consequences on the net income of the consumer of the innovation as an 
intermediate good: an increase or a reduction?
14 
•  The capacity to ensure that property rights are enforced, and therefore to limit risks of 
imitation. The presence of property rights in a country is necessary but not sufficient to 
encourage innovators to diffuse their innovations. There are asymmetries of information 
(moral hasard) between innovators and the country as regards its capacity to ensure that 
rights are enforced, and thereby to avoid opportunistic behaviours in local competitors. 
The innovator has to prove – put out signals attesting to – its capacity to ensure that the 
rights implemented are upheld. 
To sum up, the size of the innovator's potential market depends on the capacity to adopt innovations in 
the countries concerned. This, in turn, is contingent on budgetary constraints or consumers' market 
power, on facilities for accessing new markets in the case of intermediate consumption (phytosanitary 
controls, infrastructure, etc.), and on their consequences on consumers in the country in which the 
innovation originated
15. If a demand function exists, the innovation will be diffused if the property 
                                                 
14 For instance, in Mali the introduction of high-yield crop varieties into isolated villages resulted in a 100% 
increase in agricultural production and consequently in the collapse of farmers' incomes. This was due to a 
lack of access to national and international markets for the surplus production (Henry Feyt, personal paper). 
15 Hence, in the agricultural sector, if an innovator from country X distributes seeds in other countries and, in 
parallel, country X's agricultural product market opens up to competition, this will have consequences on 
competition between farmers in country X and farmers in other countries. Theoretically it can even lead to 
the disappearance of the agricultural sector in country X if production costs are too high compared to other 
countries. If farming dies out in country X, the same will apply to the demand for seed in that country. In this 
case, the innovator has to ensure that the foreign demand is sufficient. 
  7rights are credible and respected. But what are the incentives for a country to implement property 
rights? 
 
1.2. Incentives for a country to implement property rights to attract innovations and 
encourage research   
The implementation of intellectual property rights to attract innovations and direct foreign 
investments, and to boost the country's R&D, will depend on the characteristics of each country, 
particularly their demand and research capacities. Hence: 
•  A developing country does not have R&D capacities but does have a demand function that 
is compatible with the innovation supply function of the North. In this case, the country is urged to 
establish intellectual property rights in order to encourage the innovator in the North to diffuse its 
innovation in the South at the Northern market price, that is, at the average cost or the monopoly 
price of his or her innovation. The developing country can then hope for increasing direct foreign 
investments and a "good" development dynamic. This development option is heavily dependent on 
foreign investment. There is a risk of the growth being entirely contingent on an increase in the 
trade deficit, which is not sustainable. For such development to be sustainable, it has to be 
accompanied by measures such as technology transfer (primarily of production, in order to favour 
local development). 
•  A country has neither R&D capacities nor a demand function for an innovation from the 
North that is compatible with the market price in the North. There are two possibilities: 
o  The country will be willing to establish intellectual property rights if it secures a 
guarantee from the innovator in the North of access to its innovation at a 
differentiated price – e.g. the marginal production cost, to allow access by the most 
people possible to the innovative product – or of external funding (foundations). 
Uncertainty nevertheless remains on the sustainability of the diffusion of the 
innovation. 
  8o  In the absence of guarantees on the diffusion of innovation, it will be in a country's 
interests not to set up a system of intellectual property rights. In this way it may 
have access to imitations produced in countries where intellectual property rights do 
not exist, or to innovations produced in the North for the South and financed by 
foundations or public funds
16. In each country the implementation of rights blocks 
access to imitations. 
Direct foreign investments should then be increasing and create a development dynamic dependent 
on foreign countries (either in the North or else imitators in the South). This situation is sustainable 
if the diffusion of innovations and imitations is accompanied by an increase in wealth via 
technology transfer, primarily production technology. There is nevertheless still the risk of 
redistribution of surplus (royalties) which may exclusively benefit innovating countries or 
imitators, and therefore contribute very little to the growth of countries in the South. 
•  If a country has no research capacities but does have imitation capacities, then irrespective 
of its demand capacities, it will not be encouraged to set up an IP system. To avoid too much 
dependence on foreign innovations, it prefers to wait for local firms to develop their research 
activities in such a way as to have a more favourable allocation of resources, that is, with fewer 
royalties to pay to countries in the North. During this transition phase between imitation activities 
and research activities, firms carry on copying and diffusing their imitations in the local market and 
in the markets of countries which have not adopted IP rights
17. 
•  Finally, if a country has R&D activities and a demand function, implementation of IP rights 
stands to reason and firms' objective is to produce innovations to compete with those of others in 
the international market. Today India is developing a pharmaceutical industry based on innovation 
and no longer on imitation; this has required amendments to Indian legislation protecting 
pharmaceutical inventions. 
                                                 
16 For instance, in 2005 the Bill and Melinda Gates Foundation financed the distribution of Aids antiretroviral 
drugs in Africa for an amount of over US$30m. 
17 In 1968 Germany introduced pharmaceutical patents in its national laws; Italy and Sweden followed suit two 
years later. Japan recognized patentability in 1976 and Switzerland in 1977 only. 
  9The trade-off for a country is between setting up IP rights to boost research at national level, or setting 
up IP rights to promote imports of foreign innovations. This is a tricky choice: on the one hand it is a 
matter of setting up weak enough rights to have possibilities of development of research activities 
independent of the North, but at the same depriving itself of access to innovations of the North – bar 
those financed by foundations or public funds; on the other hand it consists in implementing rights that 
are strong enough to guarantee access to innovations, but at the same time deprive the country of 
research capacities in the long term. This is a particularly difficult decision to make since the 
dependence of the diffusion of innovations on outside innovators can be a source of social under-
efficiency in the long term, depending on the evolution of its research and imitation capacities, and the 
distribution of the surplus between innovative countries and others. 
  
2. Implementing an intellectual property policy 
Until now my discussion of the links between innovation and intellectual property has been 
theoretical. One of the conclusions is that optimal property rights are continuous in all three 
dimensions (height, breadth and length) and that the implementation of an optimal property right in a 
country depends primarily on consumers' capacity to adopt innovation (cultural position, financial 
capacity, capital, etc.) and on that country's research and imitation capacities.  
 
  2.1. How to choose the property rights to implement in a country 
Contrary to the recommendations of economic theory, at the operational level it is impossible to have 
different intellectual property rights for each innovation and in each country. Transaction costs are 
prohibitive and innovators have no certainty as to the size of the market for an innovation. 
 
2.1.1. Standard tools 
  10There are currently various intellectual property options available, which are supposed to cover the 
diverse types of innovation
18. These options include patents, copyright, trademarks, etc. They vary 
widely, regarding not only the innovation that they protect but also their operational characteristics 
(length, breadth and height). Thus, the scope of intellectual property rights may differ: in copyright, 
where there is plagiarism, the explicit knowledge of the existence of a former literary work is 
necessary; in the case of the patent, there may be dependence on patents about which one was not 
aware. Shapiro (2000) uses the term "hold-up" to describe this situation. At a territorial level, a patent 
is valid only in those countries in which a PCT (Patent Cooperation Treaty)
19 extension has been 
applied for, whereas protection by copyright is more common. The advantages of these standard tools 
is their universality, and hence the relative ease with which they can be used and their recognition 
throughout the world. Their drawbacks are that they are sometimes implemented in sectors or even 
countries where their effectiveness in terms of social optimum is weak or even negative. For example, 
as regards access to genes, there are risks of appropriation of life forms via an extension of patent 
rights on sequences that are too long. The social consequences can be disastrous, in respect of health 
(Aids) and food (famine) (Henry, Trommetter and Tubiana (2003)). The implementation of intellectual 
property rights can prove to be non-optimal because: the rights are not operational on a country scale; 
the rights are too strong or too weak in relation to the research capacities and/or the demand function 
of a country. 
To limit the perverse effects of standard intellectual property rights and thus obtain a second-best 
social optimum, flexibilities exist. These flexibilities are generally implemented by government, for 
instance compulsory licences (e.g. on essential facilities), and antitrust institutions  (e.g. Antitrust 
Division of the US Department of Justice) to limit situations of abuse of a dominant position. More 
simply, the conditions of intellectual protection of an innovation may be revised by law. The latter 
                                                 
18 The choice of the rent is directly related to the trade-off between more innovation and more diffusion of this 
innovation, which is complex when one refers to a particular innovation. As Tirole (2003) points out: "it will 
be even more complex when one has to define an intellectual property protection regime that is valid for the 
entire economy". 
19 A unique procedure administered by the WIPO which, with reference to the Washington Treaty of 19 June 
1970, allows for a patent to be filed simultaneously in all or some of the signatory countries of this 
convention. A single international application has the same effect as national applications filed in the 
countries covered (Source: http://hydre.auteuil.cnrs-dir.fr/dae/faitsetchiffres2003/&&_lexique.html ). 
  11option is feasible only when the social costs of the perverse effect are higher than the costs for the firm 
incurred by unstable intellectual property rights. To be encouraged to invest in R&D, firms need stable 
legal rules. Otherwise they integrate the instability (uncertainty) in their profit-maximizing model, 
which will tend to reduce their incentives to R&D. The reasoning is the same for compulsory licences 
which, to be economically and socially effective, should not be used systematically. 
The implementation of standard property rights can also lead to overlapping rights. Under-efficiency 
related to such rights may stem from rights that are too easily granted (height) or claims that are too 
easily accepted (breadth), or a combination of the two. In this context Shapiro (2000) defines "patent 
thickets" as situations in which a patent depends on a very large number of other patents
20 and 
consequently entails risks of inefficiency due to: the existence of too many beneficiaries (Heller and 
Heisenberg (1998))  – the "multiple margin" phenomenon –; the fact that the thicket is a source of 
uncertainty – one of the patent owners may refuse to grant an operating licence and block future 
research –; and high transaction costs, the anti-commons tragedy (Heller and Heisenberg (1998)). In 
this context the tool consisting of "a licence on a pool of patents" seems the most appropriate for 
limiting the perverse effects. But pools of patents are generally used in the construction of standards or 
modular innovations (ex ante complementarities), since their ex post use is often equated to anti-
competitive practices by antitrust authorities. In the past the use of licences on ex-post patent pools 
was reserved for the state, to boost economic sectors such as the aeronautics industry in the US in 
1919 and the semi-conductor industry in the 1950s. Today these licences on ex post patent pools are 
proposed by private firms and theoretically justified by the work of Lerner and Tirole (2004). These 
authors show that granting licences on an ex-post pool consisting of partially substitutable rights can 
be socially optimal if they fulfil certain conditions, particularly the existence of individual licences on 
the patents comprising the pool. In other cases, the extrapolation of models of common agencies 
(Sinclair Desgagné (2001); de Villemeur and Versaevel (2003)) to matters of collective knowledge 
                                                 
20 Golden Rice is a technology developed to enrich rice in Vitamin A, with a view to compensating for a chronic 
deficiency in populations whose staple food is rice. Three genes were inserted to complete the biosynthesis of 
beta-carotene, in addition to which the technology requires the use of transformation vectors, promoters and 
markers of resistance to antibiotics, all patented or covered by material transfer agreements (see below): a 
total of 70 items controlled by a dozen patent holders (Kryder et al. (2000)). 
  12management can be considered. They may explain the implementation, for example, of the clearing 
house mechanism
21 in the US in the plant biotechnology field (Graf et al. (2001)). 
 
2.1.2. Non-standard tools 
Apart from the traditional tools of intellectual property and their related flexibilities, other tools can be 
proposed to protect innovations: sui generis intellectual property rights, licence contracts in open 
source technologies, etc. 
* The use of sui generis rights is generally limited to well-defined sectors (as recommended by 
economic theory on optimal intellectual property rights). They are new tools, designed to be 
adjustable to particular innovations. Implementing a new right is costly but in these particular 
sectors the associated cost is inferior to the social cost relative to protection with a standard tool 
linked to flexibilities. Two examples: first, in 63 countries plant varieties (seeds) are protected 
by plant variety rights (PVR) issued by the Union for the Protection of New Varieties of Plants 
(UPOV); second, databases in Europe are protected by a sui generis right. In the former case the 
idea is to establish a right that is weaker than the patent in the scope of the protection, whereas 
in the latter case, since copyright is considered too weak to effectively protect databases, it is 
accompanied by a sui generis right that increases the breadth compared to traditional copyright. 
* The licence contract in sectors where research is organized along the same lines as open 
source software. In this framework standard protection tools are used – usually copyright – but 
it is by way of the licence contract that the diffusion of innovations is facilitated. The initial 
developer's objective is to favour the development of cascading applications, while limiting the 
risks of private appropriation by others.  
The aim of these non-standard rights is to protect the innovation while limiting the perverse effects of 
the standard right. The PVR guarantees the protection of the commercialized variety against 
                                                 
21 Graf et al. (2001) explain that the implementation of a clearing house mechanism for the collective 
management of the patents of US universities in the plant biotechnology field depends on: 
•  limiting risks related to overlapping patents, to seek and propose licences on attractive patent pools 
and/or produce innovations in the public sector (on orphan plant varieties or aimed at developing 
countries); 
•  greater negotiating power to have access to patent licences held by large biotechnology multinationals. 
  13imitations, which is the necessary condition to ensure incentives to innovate, while guaranteeing 
access to the genetic resources composing it, for research and plant breeding purposes. This access is 
open, free-of-charge and automatic (i.e. without a contract) (Joly and Ducos (1993)). Such free access 
to genetic diversity has always been demanded by plant breeders, especially in Europe. In 1991 the 
PVR was amended. Legislators revised the definition of the breadth of intellectual property, which 
amounted to redefining the notion of imitation, to limit risks of private appropriation of plant varieties 
by GMO seed producers (Trommetter (2005)). Today an imitation is a variety that is essentially 
derived from a pre-existing variety. A minimal genetic distance must exist between two varieties for 
them to be considered as independent. The breadth of the PVR is therefore limited to the 
commercialized variety and to essentially derived varieties, contrary to plant varieties protected by 
patent (US with the Plant Patent Act and the Utility Patent), where the breadth primarily concerns all 
uses of the variety and therefore requires negotiation of a licence agreement. 
The approach that led to the PVR corresponds to a research paradigm based on access to biological 
and genetic diversity, and to theoretical models of sequential and cumulative innovations (Scotchmer 
(1991, 1999 and 2005)) which reflect the organization of research in the seed sector in Europe. Today 
this model is found again in open source software, where access is free but contractualized to avoid 
risks of appropriation allowed for by current legislation
22. The logic of copyleft licences for the use of 
open source-type software (Dequiedt, Ménière and Trommetter (2006)) is very similar to the PVR 
logic. To be able to use and alter open source software it is necessary to sign licence agreements that 
may have varying characteristics
23. This may be a source of substantial transaction costs. To facilitate 
access to innovations, it is necessary to introduce contracts that limit the uses to which innovation can 
be put, especially private appropriation. Compared to the PVR which proposes automatic free access 
                                                 
22 In open source software a variety of licences is proposed to users. These may prove to be antagonistic with 
regard to certain uses. Likewise, the PVR facilitates the diffusion of varieties in countries that are members 
of the UPOV, but limits diffusion in the US where protection is double, causing risks of dependency to be 
more frequent. 
23 A few examples of licences: 
- GNU General Public Licence: this licence proposes free access and free amendments; 
- BSD Licence (Berkeley Software Distribution Licence): this licence proposes free access, free amendments and 
free redistribution of amended programs; 
- Mozilla Public Licence: this licence proposes free access, free amendments for personal use and the possibility 
of redistribution under MozPL licence. 
  14to the genetic diversity of commercialized varieties for all UPOV members, in the case of open source 
software access is contractualized, thus generating additional transaction costs. 
The drawbacks of sui generis rights are primarily related to their credibility on the international scene. 
To be adopted by innovators, these rights have to be implemented in a minimum number of countries 
so that a minimum threshold can be reached for the size of the market accessible to the innovator. If 
the right is implemented in areas that are too limited, the only certainty is that innovators will abide by 
the rules of more constraining rights, to be able to reach a sufficient market area for their innovation, 
without risks of dependence. Hence, sui generis rights that are too weak can reduce effects on 
research, since the flexibilities that they allow will not be mobilized. 
In the case of developing countries these sui generis rights have to be studied. The advantage of 
constructing a sui generis right is that it enables the legislator to take into account the specific 
characteristics of the research and development system, of the national demand and possibly also of 
environmental constraints. In the protection of plant varieties, use of a sui generis tool has often been 
interpreted as the implementation of the PVR in developing countries, but other sui generis protection 
systems can be developed. The Organization of African Unity (OAU) has proposed a system of sui 
generis  protection which defines the conditions of access to biological resources, as well as 
community rights, farmers' rights and plant breeders' rights (OUA (1999)). Despite its shortcomings, 
this document was intended to take into account the particularities of plant breeding in the countries 
concerned. In most African countries the seed sector often remains empirical and local varieties, 
although new and distinct, are generally less stable and homogeneous than seeds in the North. But 
stability and homogeneity are the conditions needed to use the regular protection tools, the PVR or 
patent. The intellectual property system proposed by the OAU is weaker than the UPOV system in its 
height, that is, what can be protected, and it can be combined with other types of protection. The 
objective is to favour the diffusion of innovations from the North without precluding the development 
  15of traditional varieties in the South
24. To that end, it is necessary for countries to grant authorization 
for commercialization, compatible with their research capacities. In seeking a social optimum, each 
country can define various conditions for a variety to be listed in the catalogue of commercializable 
varieties. In Europe commercialized varieties have to fulfil certain conditions for protection by the 
PVR (distinctness, uniformity and stability); in Africa a country can set up a PVR-type protection or a 
patent to attract innovations from the North, combined with a sui generis protection on traditional 
varieties, while simultaneously authorizing commercialization of the two types of seed
25. Farmers are 
therefore free to choose the seeds they wish to use in their fields. 
 
2.2. Limiting the perverse effects by maintaining the positive effects of rights 
The existence of different rights to protect innovations should help to limit the perverse effects of 
property rights that are too generic and inflexible, in countries of the North and the South alike. The 
co-existence of different rights nevertheless impacts on future research capacities and future markets 
for innovations. 
   
 
2.2.1. Co-existence of different rights 
The fact the PVR or patents can be used to protect seeds obtained by breeding – that is, by cross-
breeding rather than genetic manipulation – has led the EU to propose flexibility in Directive 98/44 on 
biotechnological inventions: the possibility of resorting to cross-compulsory licences in plant 
biotechnologies to solve disputes between private actors
26. These licences guarantee protection for 
innovation, with "remunerated free access" to genetic resources. Thus, when innovators cannot 
produce an innovation without infringement of an existing patent, they can request a dependency 
                                                 
24 Other tools are envisaged to protect traditional varieties. For example, Geographic Indication, recognized by 
the WTO, associates a product, a territory and, in certain cases, specific varieties used to produce it. For 
instance, in the case of the AOC Châtaignes d'Ardèche, the chestnuts are from local varieties of the Castanea 
sativa Miller, the list of which is defined in the technical regulations provided for in Article 1 of the 28 June 
2006 Decree (Marchenais (2006), personal paper). 
25 Article 27/3b of the WTO TRIPS agreement provides for the combination of rights since it stipulates that: 
"Members shall provide for the protection of plant varieties either by patents or by an effective sui generis 
system or by any combination thereof …". See 3.1 below. 
26 Directive 98/44, Section III on compulsory dependency licences. 
  16licence for the non-exclusive exploitation of the invention protected by that patent, in exchange for an 
appropriate licence fee and/or a cross-licence between the two innovations. If the patent holder refuses 
to grant a dependency licence, European Directive 98/44 stipulates that it may be compelled to do so 
by public decision (in France, the law courts). Even if the institution of a system of compulsory 
dependency licences between varieties protected by PVR and GMOs protected by patent limits the 
risks of impeding subsequent research, seed companies switch from a system of free access to one of 
payment for access. In Europe access to genetic diversity is no longer automatic, nor free, but remains 
a priority. Transposition of the biotechnology directive in French law, in December 2004, proposes 
another flexibility by adding an article to limit the scope of patent protection (Article / 613 5-3)
27. The 
aim of this article is to guarantee access to genetic diversity, including GM varieties that contain one 
(or more) patented gene(s), since the patent covering a gene in a GMO is no longer extended to the 
entire plant. Free access exists to the genetic diversity of the GMO, minus the patented gene. Use of 
this freely accessible genetic diversity is facilitated by biotechnological innovations such as “marker 
assisted breeding” which make it possible not to select the results of cross-breeding in which the 
patented gene is present. Thus, in the transposition to French as well as German and Swiss legislation, 
access to genetic diversity is once again open, automatic and free-of-charge, but with other constraints, 
particularly on access to seed markets. 
International conventions can also limit the use and diffusion of innovations. To favour the protection 
and diffusion of agricultural genetic resources, the FAO international treaty on phytogenetic resources 
takes into account the fact that different types of intellectual property exist, which have diverse effects 
on the genetic resources in innovations. If an innovator protects an innovation by PVR or any other sui 
generis system that allows free access to genetic diversity, there is a voluntary contribution to an 
                                                 
27 "Art. L. 613-2-2. – Subject to the provisions of Articles L. 613-2-1 and L. 611-18, the protection conferred by 
a patent to a product containing genetic information or consisting of genetic information extends to any way 
in which the product is incorporated and in which genetic information is contained and has the indicated 
function. 
"Art. L. 613-2-3. – Protection conferred by a patent relative to a biological material which, through an 
intervention, has determined properties, extends to any biological material obtained from that biological 
material by reproduction or multiplication and endowed with those same properties. 
"Art. L. 613-5-3. – The rights conferred by Articles L. 613-2-2 and L. 613-2-3 do not extend to the acts 
accomplished with a view to creating or discovering and developing other plant varieties." (Personnal 
translation)  
  17international compensation fund. If an innovator protects an innovation by patent, with a risk of 
blocking access to genetic resources, there is a compulsory payment to the compensation fund. There 
is therefore an incentive to maintain free access to the resources relative to the amount of compulsory 
compensation to the international fund. The purpose of this fund is to manage and preserve genetic 
resources and to finance operations of plant improvement in favour of countries of the South. 
However, with changes in the status of agricultural genetic resources, only the plants covered by the 
FAO international treaty remain freely accessible. What about those not covered by the treaty and 
therefore covered by the convention on biological diversity? Take the case of the tomato, for instance, 
which is not covered by the international treaty. Access to genetic resources depends on the 
sovereignty of states and the usual contractual clauses with the provider of genetic resources. In 
contrast, the commercialized variety is freely accessible for competitors since it is covered by a PVR. 
In this context two situations are possible: 
* The firm does not enter into a contract with the supplier of genetic resources and takes the risk 
of using the resource without authorization. Since there are multiple hybrid origins, it is very 
difficult to identify ex post the biological material effectively used in breeding programmes 
(local cultivars, protected varieties, etc.). A risk of free-riders therefore exists for the owners of 
the resource. This risk can be limited by implementing mechanisms of traceability to identify 
the material effectively used, for instance the certificate of origin and the process of disclosure 
of the origin of the biological material when the application for an intellectual property right and 
particularly for a patent is made
28. However, depending on the definition of the origin of the 
material
29, the implementation of these certificates can very quickly become complex in the 
seed sector, due to multiple overlaps, with exponentially increasing transaction costs; 
* The firm enters into a contract. It may be faced with particular clauses – e.g. "the material can 
be used in R&D activities whose innovations will be protected by patent and not by PVR" – or 
equally tight constraints. For instance, the firm may be encouraged to protect its innovation with 
                                                 
28 The implementation of these tools is under negotiation at the Convention on Biological Diversity 
29 Negotiations are under way at the FAO to define the notion of "origin of the material". Should a laboratory, 
whether public or private, be obliged to disclose the last transaction (the person or laboratory that gave it the 
material) or the first transaction on that material (who is the original owner of the material)? 
  18an IP system other than the PVR, since it is potentially the only one to pay a licence fee on its 
innovation. In this case it would want to limit the possibilities of hold-up of its innovation by 
competitors
30. 
The PVR is still the tool for easy access to agricultural genetic resources but its influence may decline 
due to the change of status for basic genetic resources. This potential reduction of the role of the PVR 
in the protection of plant varieties will also impact strongly on future research. Thus, as Bellivier and 
Noiville (2006) point out: "the 'INRA 258' maize variety, created from two American, one Spanish and 
one French variety, could probably not have been developed without years of negotiations with the 
countries of origin had the Convention on Biological Diversity system not been applied". 
This co-existence of various tools does not facilitate seed firms' access to the seed market. Wanting to 
distribute European seeds in the US is risky, to say the least, due to the fact that there are no 
compulsory cross licences with the US. Likewise, since France and Germany have more flexible 
legislation than other European countries, in transposing Directive 98/44 on the non-coverage of 
content they can modify the conditions of dissemination of French and German seeds throughout the 
rest of Europe. They could prove to be dependent on other varieties, in accordance with current 
legislation. Moreover, applications by European firms for PVR protection in the US are very few in 
number compared to applications for protection by the Plant Patent Act (UPOV (2005))
31. Likewise, 
the varieties developed by seed firms in the US and protected by the Plant Patent Act or the Utility 
Patent will be protected only by a PVR in Europe, if they are disseminated there (see Box 1). 
 
Box 1: Dissemination of seeds between Europe and the US 
In Europe:  
* 3,077 PVR were granted in 2004, of which 507 to foreign residents, of which 21 from the USA. 
                                                 
30 A limit of the PVR is that in the case of research on resistance, certain functions which are costly to identify 
and transfer can easily be copied by competitors. The notion of essential derivation should probably be 
extrapolated to these situations. 
31 These figures are biased by the fact that the conditions for commercializing seeds in the US are more flexible 
than in Europe, so that many varieties (primarily hybrid varieties) are commercialized there without being 
protected (secrecy). 
  19In the USA: 
* 421 PVR were granted in 2004, of which 33 from foreign residents, of which 11 from the EU. 
* 1,016 Plant Patent Act patents were granted in 2004, of which 588 to foreign residents, of which 455 
from the EU 
* over 200 Utility Patents were granted on plant varieties in 2004 
Source USPTO and UPOV (2005) 
 
2.2.2. Creating research consortiums 
To avoid the risk of being blocked by intellectual property rights that are too far upstream and 
too broad, both public and private research institutions propose an alternative to the collective 
management of intellectual property and to patent pools: the creation of a new way of organizing 
research, based on new collective and cooperative relations in the pre-competitive phases. The 
objective is to define the operating rules of research consortiums so that: - they are economically and 
socially effective by limiting, for example, risks of opportunistic behaviour associated with 
asymmetries of information (moral hazards and adverse selection); - they are not subject to the rules of 
competition law: there is private access of the members of the network to certain information; there 
are some delays in the diffusion of certain information within the network; there is little or no co-
ownership of patents. 
Thus, the main objective of the creation of consortiums on structural genomics is to accelerate 
the production of new protein structures from the crossing of different partial gene sequences found in 
public databases (Williamson (2000)). Thus, in the framework of the Single Nucleotide Polymorphism 
(SNP) consortium, over 300,000 human SNPs have been put into the public domain (Williamson 
(2000))
32. This research is financed by private funds and is carried out by public and private research 
                                                 
32 The members of the consortium are: Wellcome Trust; APBiotech; AstraZeneca PLC; Aventis; Bayer AG; 
Bristol-Meyers Squibb Company; F. Hoffmann-LaRoche; Glaxo Wellcome PLC; IBM; Motorola Novartis; 
Pfizer Inc; Searle; SmithKline Beecham PLC. The work financed by the consortium is carried out by four 
research institutes: Stanford Human Genome Center; Washington University; Wellcome Trust's Sanger Centre 
and Whitehead Institute. Each member's financial participation is US$3m. Any new participant in the consortium 
has to pay this sum as an entry duty. The Wellcome trust contributed US$14m (Williamson (2000)). 
 
  20institutes. The aim is to use these public data to discover interesting genes more quickly, for 
developing new drugs (patentable innovations), by cross-referencing different databases without 
having to worry about the existence or not of IP rights on the SNP used (i.e. leaving free access to 
sequences for all functions). 
Likewise, the "Génoplante" contract (a French research consortium of public labs and private 
firms) provides for the more fundamental patents to be filed by research institutes and the more 
applied ones to be filed by private enterprises. The contract furthermore provides for free compulsory 
licences between members of the consortium. 
Finally, the open source model is mobilized in biotechnologies where "open source 
biotechnology" refers to the possibility of extending the principles of commerce-friendly, commons-
based peer production exemplified by open source software development to the development of 
research tools in biomedical and agricultural biotechnology. Feldman (2004) notes that "fledgling 
efforts exist to establish open-source projects in biotechnology. Following copyleft, participants agree 
that advances in the technology must remain as openly available as the original technology". 
Hence, within consortiums and networked research activities, the definition of rules is a 
prerequisite for each research project. As Cassier and Foray (1999) show, an absence of rules at the 
outset automatically leads to opportunistic behaviours and to the end of research networks. The 
introduction of rules is therefore necessary to limit moral hazard situations, since the partners' actions 
cannot all be observed. There is a twofold uncertainty on the real activity of genetic evaluation and on 
the dissemination of information to the members of the network. The rules on the conditions of 
participation and even exclusion from the consortium are therefore central. If there is a sharing of costs 
and results, the approach has two steps: participate or not in common research (choice between 
participating or not), then set the rules of sharing and the levels of each partner's research efforts, etc. 
The general conclusion is that the more intense the competition is downstream, the more a cooperative 
agreement can help to reduce the overall effort. This type of difficulty is partly resolved with models 
based on partial cooperation agreements (Bhattacharya and Sappington (1992); Bhattacharya and 
Guriev (2004)). 
  21In this system of research coordination, no patents are filed on the results of pre-competitive 
research phases. There is a contractualized free access to genetic diversity, whereas the PVR model 
proposes that access to genetic resources be free and non-contractual for seed companies and therefore 
without transaction costs. Patents on life forms and especially their excesses lead to contractualization 
(economically and socially necessary) of free access, the only guarantee of private non-appropriation 
of genetic resources and of a return to an organizational model close to the PVR. 
 
3. How can the TRIPS agreements be interpreted? 
In this section we analyse whether the construction and implementation of the WTO TRIPS 
agreements and the bilateral TRIPS+ agreements are consistent with the propositions in the first two 
sections. There we examined how IP rights can be defined and implemented so that innovations are 
achieved and diffused in a context of maximization of the social welfare. 
 
3.1. How to choose IP rights under the TRIPS agreements 
The TRIPS agreements require the implementation of a system of minimal intellectual property 
protection. This means that when it comes to intellectual property, a country can do more but cannot 
do less. To expand the area of the market for innovations in the North, developing countries can set up 
more restrictive IP rights. In other words, there is no superior threshold above IP rights. Nevertheless, 
two superior thresholds are recognized by the WTO and can be imposed by a country's government: 
the general interest endorsed by compulsory licence; and abuse of a dominant position sanctioned by 
the relevant authorities. 
Concerning operationality, we will now focus on the implementation of Article 27 of the TRIPS 
agreement relative to patents. The aim is to generalize the patent system world wide, but at the same 
time to provide for flexibilities (primarily by limiting the height of patents), with: the possibility of 
  22excluding inventions from patentability, Article 27 2.
33 and 27 3.
34 ; the application of exceptions to 
the rights conferred, Article 30 and to a lesser extent Article 31.   
Restrictions also exist on the possibility of excluding inventions from intellectual property; this is the 
case of plant varieties in Article 27 3/b
35. This article stipulates that a country is obliged to grant rights 
on plant varieties, but provides for flexibility on the tool to implement since it authorizes recourse to 
sui generis rights. A known sui generis system to protect plant varieties is the PVR, but other systems 
can be implemented, such as the OAU system described above.
36
Of the four points favourable to innovation, presented by Aghion and Howitt (1998)
37, very few are 
present in developing countries and we may wonder whether starting with the implementation of Point 
(4) "protection against ex post competition in the product market" is the most effective way to favour 
development and the diffusion of innovations in developing countries. On 30 November 2005, the 
WTO provided for a degree of flexibility in the implementation of these agreements, for the least 
developed countries: "least developed country members as a group were granted extension of 
transitional period for 7.5 years to apply the provisions of the TRIPS Agreement – that is, 'until 1 July 
                                                 
33 "Members may exclude from patentability inventions, the prevention within their territory of the commercial 
exploitation of which is necessary to protect ordre public or morality, including to protect human, animal or 
plant life or health or to avoid serious prejudice to the environment, provided that such exclusion is not made 
merely because the exploitation is prohibited by their law." 
34 "Members may also exclude from patentability: 
(a)  diagnostic, therapeutic and surgical methods for the treatment of humans or animals; 
   (b) plants and animals other than micro-organisms, and essentially biological processes for the production 
of plants or animals other than non-biological and microbiological processes." 
35 "However, Members shall provide for the protection of plant varieties either by patents or by an effective 
sui generis system or by any combination thereof."   
36 The TRIPS agreements allow for the co-existence of several rights, which should be favourable for the 
creation, diffusion and commercialization of traditional seeds.  
37 To sum up, the following are favourable for innovation: 
1) competition for innovation; 
2) ex ante competition in the product market; 
3) diffusion of knowledge accumulated on the occasion of previous innovations; 
4) protection against ex post competition in the product market. 
      If, as is often the case, the restriction of competition (4) is obtained by a temporary monopoly on the use of 
certain knowledge, Conditions (1), (2) and (3) are all affected adversely for innovation.  
  232013, or until such a date on which they cease to be a least-developed country Member, whichever 
date is earlier' ".
38  
For the agricultural sector, a question relative to the adoption of IP rights is: do developing countries 
today have access to the most effective seeds for their agricultural production? The answer is: this 
depends on the IP system, on research and imitation capacities, and on the existing demand in the 
developing countries. This answer highlights the fact that the IP system is simply one of the elements 
that favour the creation and diffusion of innovations world wide. 
The world seed market is currently considered to be worth US$50bn, US$30bn of which are traded 
commercially. GMO seeds currently account for US$10bn. As regards research in agricultural 
biotechnologies, 96% of R&D expenditures are made in OECD countries and 70% are by private 
enterprise. In this context, Box 2 presents contrasting situations. Some countries import varieties from 
the North, others far less so. In Argentina over 60% of the varieties protected by PVR are produced by 
local seed firms. This is therefore an effective tool for Argentina since it has allowed both diffusion of 
innovations from the North and the development of a competitive seed sector (owing to R&D 
activities). In countries which benefit from these transfers of varieties, some are totally reliant on R&D 
in the North. For instance, in Kenya the 37 PVR of foreign origin concern rose varieties, as the 
production of roses for export is now being developed locally. Kenyan farmers are therefore simply 
producers under contract with major groups. These local producers hardly benefit from the value 
added and there seems little hope that this situation will change in the future. Even if the will to 
nurture fair trade exists, studies show that transport, storage and distribution absorb a large share of the 
value added. Production accounts for no more than 10% of the sales price (anonymous (2005)). 
Moreover, because of low production costs, Ethiopia is actually a major competitor to Kenya.   
In most countries of the South the institution of intellectual property has not boosted the local seed 
sector via technology transfer or direct foreign investments. Is this irreversible or are we in a 
transitional phase? 
                                                 
38 This decision does not apply to pharmaceutical products, which LDCs are not required to fully protect until 
2016 as a result of an extension granted to them in 2002 (Doha agreement). 
  24There is a risk of local seed firms disappearing and thus of local farmers becoming dependent on 
breeders in the North, which in the long run could prove to be under-efficient. To limit these risks, in 
addition to the flexibility related to the choice of a mode of protection, the TRIPS agreements enable 
countries to implement compulsory licences in the general interest (health, under-nourishment and 
poverty)
39. Such compulsory licences have a sphere of application which is generally limited to the 
borders of a country. But we have seen that many developing countries have capacities for neither 
research nor imitation, and are therefore unable to implement the threat of a compulsory licence. In the 
Doha  declaration on the TRIPS agreement and public health, a flexibility clause is added: the 
possibility of benefiting from products manufactured at regional level is provided for – but the 
conditions of implementation of a compulsory licence are complex. 
 
Box 2. Diffusion of innovations from countries of the North to developing countries in 2004 
In Latin America 
* Argentina: 230 PVR of which 114 by non-residents, of which 101 from countries of the North 
* Brazil: 121 PVR of which 30 by non-residents, of which 26 from countries of the North 
* Other (9 countries): 380 PVR of which 327 by non-residents, of which 209 from countries of the 
North 
In Eastern Europe 
* Russia: 417 PVR of which 8 by non-residents, of which 6 from countries of the North 
* Other (14 countries): 504 PVR of which 128 by non-residents, of which 101 from countries of the 
North 
In Africa 
* South Africa: 277 PVR of which 198 by non-residents, of which 184 from countries of the North 
* Kenya: 41 PVR of which 41 by non-residents, of which 37 from countries of the North 
                                                 
39 Henry (2004): "In the case of a compulsory licence, a qualified public authority charges a patent holder to 
grant a licence to an operator nominated by the said authority, in exchange for a remuneration which it 
determines. This is a last resort, envisaged only if the patent holder takes advantage of its (temporary) 
monopoly position in relation to the public interest concerned. 
  25In Asia 
* China: 87 PVR of which 4 by non-residents, of which 4 from countries of the North 
* South Korea: 477 PVR of which 273 by non-residents, of which 270 from countries of the North 
Source UPOV (2005) 
 
Despite reservations regarding TRIPS, flexibilities do exist in these agreements, in both the IP tools 
and in their implementation (primarily compulsory licences, differentiations in the deadline for 
implementing the TRIPS, etc.). These flexibilities may allow for a second-best social optimum to be 
attained in a context of sustainable development. But are they really applied in developing countries? 
 
3.2. The TRIPS+ agreement 
The bilateral TRIPS+ agreements are free trade agreements signed between a developing country and 
either the US or the EU. These agreements are usually contracts in terms of which the developing 
country will implement intellectual property rights that go beyond the TRIPS agreement 
recommendations (primarily by overruling the flexibilities) and often beyond the IP rights of 
developed countries (e.g. by limiting recourse to compulsory licences
40). In this context, the US and 
Europe seek to impose their IP system on developing countries, for example in the protection of plant 
varieties. Patents are supported by the US and PVR by Europe. The system of protection opted for by 
each country will have an impact at national level – on research, competition and markets – as well as 
international level by expanding -respectively reducing- the perimeter of the market for European 
innovations protected by PVR, to the detriment –respectively benefit- of innovations from the US, 
protected by patent. This race for bilateral agreements, between the EU and the US, does not take 
into account the real needs of developing countries in terms of intellectual property. For instance, 
imposing the PVR or patent does not protect local cultivars which in certain countries account for over 
                                                 
40 Henry (2004): "In 1993, under pressure from the US, by an amendment to the law passed in the preceding 
year, Thailand agreed not to use compulsory licences, irrespective of the circumstances. This legal ban was 
lifted in 1999 when Thailand introduced into its law the TRIPS agreements concluded at the WTO in 1995". 
  2680% of the seeds sown. What future is there for the seed sector in developing countries and what are 
the consequences for their farmers? Three scenarios can be envisaged: 
* Scenario A, the patent: country X has weak R&D capacities in the seed sector, associated with 
a system of patents on plant varieties. The future of its agriculture therefore depends exclusively 
on seeds produced abroad and possibly technology transfers for producing and/or carrying out 
seed innovations in the country. This means that there are risks of dependence of its agriculture 
on agri-chemical and seed companies from the North. In this scenario, trade advantages exist in 
country X's favour, but it is necessary to anticipate the distribution of this gain between the 
actors and, in particular, the amount of royalties paid to the innovator in the North (share of the 
surplus captured by the innovator). 
* Scenario B, the PVR: a country has little R&D in the seed sector but a PVR to protect plant 
varieties. It is totally dependent on seeds from the North if authorization to market seeds is 
associated with conditions of granting a PVR, which is the case for instance in France 
41. The 
consequences are then the same as in the case of the patent: the flexibility of the PVR compared 
to the patent cannot be mobilized by local selectors as their varieties do not fulfil the conditions 
of certification, and therefore of commercialization. 
* Scenario C, the PVR associated with a sui generis tool for recognizing local cultivars
42. In this 
context, two intellectual property rights can co-exist
43 and two types of variety can be 
commercialized (improved varieties from the North and local cultivars). Any plant breeders 
from country X can use the genetic diversity of protected varieties in its own breeding 
programmes. The dependence is then less strong and above all less irreversible than in the case 
of patent protection. 
Consequently, the IP system opted for impacts on the country's capacity to participate in the creation 
of future technical change, and therefore on its level of dependence, for its growth, on innovations 
                                                 
41 This situation is actually more flexible in France, particularly for participative breeding. April 17 2007 the 
European council adopt a directive on “conservation varieties” that will facilitate the inscription on the 
common catalogue and the commercialisation of old and traditional plant varieties.   
42 Whether it is a sui generis system close to the OAU model or a Geographic Indication. 
43 Note that this co-existence of rights is consistent with Article 27/3b of the TRIPS agreement.  
  27produced in countries of the North. The above scenarios are a key element for the future development 
of farming world wide. IP issues should therefore be dealt with at the same level as negotiations on 
direct or indirect aid for agricultural production (Drouhin, Munier and Trommetter (2005)). This 
directly raises the question of: who benefits from the agreement? 
* No evaluation has been performed yet of the winners and losers of the extension of IP to 
developing countries. Case studies do nevertheless exist, especially in Latin America, in which 
the links are identified between IP, research cooperation, and direct foreign investments. The 
few available results (Forero Pineda (2006); Roffe (2006)) show that developing countries are 
not the winners in these bilateral agreements. Roffe points out that: "The countries of the 
Andean Group (Bolivia, Colombia, Ecuador, Peru, Venezuela) have experienced higher royalty 
fees since the Uruguay GATT Agreement. There has been an increase in patent applications, 
but 85% still from non-residents – mostly from 5 countries including US, UK, Japan – so the 
patent system is not benefiting the people in these countries". Moreover, competition between 
developing countries is fuelled by the EU and the US, which can collaterally create imbalances 
in regional agreements such as the Andin Pact (Drexl (2005))
44. 
* The bilateral TRIPS+ agreements and their consequences on R&D in developing countries are 
therefore somewhat removed from the TRIPS philosophy and standard economic theories. In 
these contracts, taking the particular characteristics of developing countries into account is not a 
priority. We may well wonder what the incentives are for countries of the South to sign such 
bilateral contracts. 
In a context of sustainable development, negotiations on intellectual property certainly have 
advantages in terms of growth, but they also entail risks for developing countries, particularly with the 
TRIPS+ bilateral agreements. Even though at the WTO level it was acknowledged that the TRIPS 
agreements were too restrictive for the poorest countries – so that these countries were given until 
2013 (even 2016 for the pharmaceutical sector) to implement them – some of these countries have 
                                                 
44 "After the U.S. had forced Ecuador to agree on higher domestic IP standards, the Andean Community Court of 
Justice in Quito held that the bilateral agreement violated the law of the Community", Drexl (2005). 
  28nevertheless signed TRIPS+ agreements with the USA or EU. Those countries now have rights out of 
all proportion to their R&D capacities and their national demand functions. 
 
3. Synthesis and conclusions 
In this paper I have discussed the fact that economists define optimal IP rights as a continuum of 
options in three dimensions: height, breadth and length. At the operational level we have seen the 
impossibility of multiplying rights indefinitely (due to prohibitive transaction costs), as well as the use 
of a limited number of IP tools which have led to the implementation of flexibilities. These 
flexibilities are designed to limit certain perverse effects of rights ill-adjusted to the characteristics of 
some economic sectors (agricultural biotechnologies, pharmacy, etc.). They serve to offset the 
incompleteness of the system of IP rights in relation to possible types of innovation and to the 
characteristics of the countries in which they are developed. 
The examples developed in this paper show the extent to which a country's choice of an IP system and 
related flexibilities has to be made strategically in relation to certain characteristics: capacities for 
imitation, research and adoption of innovation by consumers, size of national markets, capacity of 
access to international regional markets, capacities to enforce the IP systems in place (credibility of the 
law), and so on. Flexibilities necessarily have a cost but which has to be compared to the cost for 
society had they not existed. They are moreover included in the TRIPS agreements, even if the 
implementation of the compulsory licence in the Doha agreement on drugs seems particularly complex 
and therefore a source of high transaction costs. 
These flexibilities – justified by economic theory due to the incompleteness of the IP rights system in 
some countries – are nevertheless challenged in the case of bilateral TRIPS+ agreements. In exchange 
for relinquishing them, the US and EU undertake to facilitate developing countries' exports, primarily 
of goods from primary production and therefore with a low value added. Is this reasonable in a 
sustainable development approach? The answer is clearly no, for there are risks of the developing 
countries remaining constrained to produce these goods with a low value added, since the North still 
has the monopoly on innovation. Apart from some countries – including, inter alia, India, China and 
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